Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Sun Pharmaceuticals Industries's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 26.66%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
BOM:524715's 3-Year ROIIC % is ranked better than 75.21% of 944
companies
in the Drug Manufacturers industry
Industry Median: 3.565
vs BOM:524715: 26.66
Sun Pharmaceuticals Industries (BOM:524715) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Sun Pharmaceuticals Industries 3-Year ROIIC % Related Terms
Sun Pharmaceuticals Industries 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sun Pharmaceuticals Industries 3-Year ROIIC % Chart
BOM:524715 vs ZTS, UTHR: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sun Pharmaceuticals Industries's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sun Pharmaceuticals Industries 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sun Pharmaceuticals Industries's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Sun Pharmaceuticals Industries's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Sun Pharmaceuticals Industries (BOM:524715) has a 3-Year ROIIC % of 26.66 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Sun Pharmaceuticals Industries and its competitors. This is 22% below median its historical median of 34.21. According to the industry distribution chart, Sun Pharmaceuticals Industries ranks #234 out of 944 companies in the Drug Manufacturers industry, placing it in the top 24.8%.
Is Sun Pharmaceuticals Industries' 3-Year ROIIC % too high?
Sun Pharmaceuticals Industries' current 3-Year ROIIC % of 26.66 is 22% below median its 10-year median of 34.21. The Drug Manufacturers industry median 3-Year ROIIC % is 3.57. Sun Pharmaceuticals Industries' value of 26.66 is 647.8% above this industry median. Based on the distribution chart, Sun Pharmaceuticals Industries ranks #234 out of 944 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sun Pharmaceuticals Industries has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sun Pharmaceuticals Industries' 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sun Pharmaceuticals Industries ranks #234 out of 944 companies for 3-Year ROIIC %. This places Sun Pharmaceuticals Industries in the top 25% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.57. Sun Pharmaceuticals Industries' value of 26.66 is 647.8% above this benchmark. While the company's 10-year median is 34.21 vs. the industry median of 3.57, Sun Pharmaceuticals Industries has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.57, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sun Pharmaceuticals Industries's current 3-Year ROIIC % of 26.66 is 647.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Sun Pharmaceuticals Industries and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sun Pharmaceuticals Industries's current 3-Year ROIIC % is 26.66, which is 22% below median its own 10-year median of 34.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sun Pharmaceuticals Industries stock overvalued right now?
Based on GuruFocus' analysis, Sun Pharmaceuticals Industries (BOM:524715) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,960.10, compared to a current price of ₹1,920.10 — trading 2% below its estimated fair value. The current 3-Year ROIIC % is 26.66, which is 22% below median its 10-year median of 34.21 and 647.8% above the Drug Manufacturers industry median of 3.57. Sun Pharmaceuticals Industries' overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Sun Pharmaceuticals Industries (BOM:524715), the current 3-Year ROIIC % is 26.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sun Pharmaceuticals Industries (BOM:524715) Overvalued in 2026?
Based on GuruFocus' analysis, Sun Pharmaceuticals Industries stock appears to be undervalued.
The current stock price of ₹1,920.10 is trading 2% below its estimated GF Value™ of ₹1,960.10.
GuruFocus considers Sun Pharmaceuticals Industries to be Fairly Valued.
Key valuation signals for BOM:524715:
3-Year ROIIC %: 26.66 (22% below median its 10-year median of 34.21)
GF Value™: ₹1,960.10 vs. price of ₹1,920.10 (2% below fair value)
Industry Position: 647.8% above the Drug Manufacturers median (#234 of 944)
No single metric tells the full story. See the BOM:524715 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sun Pharmaceuticals Industries Ltd is India's generic pharmaceutical manufacturing company. The company's substantial markets are the U.S. and India to make up the majority of revenue. The remaining is spread across both emerging and developed markets. In addition to generics, the company also produces and distributes name-brand formulas to specific geographies. It maintains manufacturing and research and development facilities globally to serve its markets but is majorly based in India.
89GF Score
Get the complete analysis for BOM:524715
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524715 has been successfully added to your 
